Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate ... in users of Novo Nordisk's GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in ...

One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class ...

and diabetes. The new portal could stir up more business for Pfizer drugs, though the company said patients won't be steered ...

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...

LUPKIN: The Pfizer platform mirrors a similar direct-to-consumer offering Eli Lilly launched earlier this year for its diabetes, obesity and migraine drugs. Lilly said last week that it will also ...

For too long, middlemen like pharmacy benefit managers have taken advantage of the complexity of the drug supply chain to ...

NurPhoto / Contributor / Getty Images Pfizer said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial. The pharma ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. Pfizer’s oncology chief has warned that the Biden administration’s drug price reforms could hurt ...

Pfizer said there are currently no Food and Drug Administration-approved treatments for cachexia, which affects about nine million people worldwide and can reduce a person's ability to tolerate ...

Pfizer’s experimental cancer weight loss drug helped patients regain weight in a mid-stage study giving fresh promise for the dangerous muscle-wasting condition Pfizer Inc.’s experimental drug ...